CHAMPIONS ONCOLOGY, INC.
HACKENSACK, NJ

Ronnie Morris, MD, was most recently one of the founders of MDVIP, the national leader in personalized healthcare. Serving as a board member, medical director and part of the executive management team, Dr. Morris helped build and manage MDVIP, a company that grew to a network of 400 doctors within 29 states servicing 125,000 consumers/patients. In December 2009, MDVIP was acquired by the Procter and Gamble Co. Prior to MDVIP, Dr. Morris was the chief medical officer and executive VP of AllianceCare, a 1500-plus-employee company that provided home healthcare, physical therapy and doctor visits for homebound patients. At AllianceCare, Dr. Morris developed and operated the physician house call division of the business, and he was the general medical director for the company. He was the managing partner of a large multispecialty group that was acquired in 1998 by ProMedCo. Dr. Morris is a board-certified internist and until 2004, he had a private practice in Boca Raton, Florida. He has been a consultant for many pharmaceutical companies, including Pfizer, Merck and AstraZeneca. Angela M. Davies, MD, FRCP(C) joined Champions Oncology in January 2014 as the company’s chief medical officer. Most recently, Dr. Davies served as chief medical officer at Novocure, where she had global responsibility for the organization’s clinical development program and commercial safety. Dr. Davies previously served as chief medical officer at OSI Pharmaceuticals where she led the oncology clinical development program for Tarceva (erlotinib) and the pipeline compounds. Prior to OSI she was associate professor of medicine at University of California, Davis where she practiced as a medical oncologist specializing in thoracic malignancies and development therapeutics. Dr. Davies is a board-certified internist and medical oncologist. She obtained her medical degree and completed her specialty medical training at McMaster University, Hamilton, Canada and University of Toronto, Toronto, Canada. Philip Breitfeld, MD has more than 30 years of experience in oncology and was most recently Global Vice President at Quintiles, responsible for the Therapeutic Centers of Excellence. Prior to that, he led the Oncology Center of Excellence at Quintiles where he worked with many large, mid-size and emerging biopharmaceutical firms. He held senior clinical development positions at Merck KGaA (EMD Serono in the US), where he led oncology development in the US, and at BioCryst, where he led oncology development and was Associate Chief Medical Officer. Prior to his career in industry, he held academic positions at Harvard, University of Massachusetts, Indiana University, and Duke. He has approximately 50 publications in the literature dealing with basic cell and molecular biology, and translational and clinical oncology. He was trained in Pediatric Hematology/Oncology at the Dana-Farber Cancer Institute, was a visiting scientist at the Whitehead Institute at MIT, received his medical degree (MD) from the University of Rochester, and his undergraduate degree (AB in chemistry) from Princeton. Dr. Breitfeld is also a Director on the Company’s Board of Directors. David Miller serves as the chief financial officer at Champions Oncology, Inc. Mr. Miller served as vice president of finance and Operations at DMCWW, LLC. From January 2006 to March 2010, he served as the chief financial officer of NAF Funding, LLC. From January 2000 to December 2005, he served as vice president of finance and Operations at IDT Corp., where he led the creation and growth of the consumer phone services division to over one million customers of local and long distance service. From 1997 to 1999, he served as an assistant vice president of the internal audit department at Deutche Bank. He also held senior accountant positions at Schonbraun, Safris, Sternlieb, LLC and Margolin, Winer and Evans. He is a Certified Public Accountant. He holds a B.S. from Yeshiva University in 1991 and an MBA from Fordham in 1999. David DeOrnellis joined Champions Oncology in June 2015 and serves as Vice President of Global Laboratory Operations, overseeing all aspects of the in vivo program, the Quality Management System, and regulatory compliance. Mr. DeOrnellis has twenty years of experience in biomedical research. Most recently, he served as Global Director of Quality Assurance at Harlan Laboratories, where he was responsible for the Quality Management System and Training Program for nineteen sites in eight countries. Immediately prior, he was the Associate Director of Technical Services at Novartis Institutes for BioMedical Research where he implemented a Technical Services team to provide in vivo study and surgical support, training, and colony management to meet the research needs for two Novartis divisions. Mr. DeOrnellis holds a BS from Arizona State University and maintains certifications through AALAS, PRIM&R, and ASQ. Champions Oncology Helping to advance your oncology drug development portfolio with a superior end-to-end research and development service platform Even if you don’t see a job currently posted that meets your qualifications, we are always looking for exceptional people with skills and experience in the following areas: Business development success in the pharmaceutical industry. Champions Oncology, Inc., is an equal opportunity employer. Champions Oncology Helping to advance your oncology drug development portfolio with a superior end-to-end research and development service platform Champions Oncology Helping to advance your oncology drug development portfolio with a superior end-to-end research and development service platform Your proactive decision to add Champions TumorGraft technology to your cancer treatment toolkit can increase your chances of success. Our team of scientists is ready to help you explain the benefits of Champions TumorGraft patient-derived xenograft (PDX) models to your oncologist. Your doctor is your primary partner in your treatment and is part of the decision to include Champions TumorGraft technology as part of your regimen. It is important that you talk to your doctor as soon as possible about your desire to add Champions TumorGraft PDX models to your treatment plan.